Cargando…

1591. Infectious Outcomes of Levofloxacin Prophylaxis in Obese vs. Non-obese Patients with Hematologic Malignancies

BACKGROUND: Levofloxacin given at a standard dose of 500 mg daily is recommended for antibacterial prophylaxis in patients receiving myelosuppressive chemotherapy. Obese patients have been shown to exhibit enhanced clearance of levofloxacin and may be at risk for prophylactic failure. METHODS: This...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kurtti, Amanda, Fritz, Kelly, Elofson, Kathryn, Benefield, Russell
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254330/ http://dx.doi.org/10.1093/ofid/ofy210.1419

Ejemplares similares

2685. Oral Third-Generation Cephalosporins vs. Levofloxacin for Antibacterial Prophylaxis in Neutropenic Patients with Hematologic Malignancies
por: DeVoe, Catherine, et al.
Publicado: (2019)

1595. Impact of Levofloxacin for the Prophylaxis of Bloodstream Infection on the Gut Microbiome in Patients with Hematologic Malignancy
por: Ziegler, Matthew, et al.
Publicado: (2018)

Breakthrough Bacteremia with Meropenem-resistant Pseudomonas aeruginosa in Hematologic Malignancy Patients Receiving Levofloxacin Prophylaxis
por: Hakki, Morgan, et al.
Publicado: (2017)

Prophylaxis with levofloxacin: bacterial infections and antimicrobial resistance in hematological malignancies
por: Campos, Claudio Penido
Publicado: (2014)

Impact of Levofloxacin for the Prophylaxis of Bloodstream Infection on the Gut Microbiome in Patients With Hematologic Malignancy
por: Ziegler, Matthew, et al.
Publicado: (2019)

2109. Liposomal Amphotericin B-associated Nephrotoxicity in Obese and Non-obese Patients
por: Tritle, Brandon, et al.
Publicado: (2019)

Case Report: Infectious prophylaxis in hematological malignancies
por: Passucci, Mauro, et al.
Publicado: (2023)

1591. Updated Fluoroquinolone MIC Breakpoints: Impact on Susceptibility Rates in the United States
por: Flamm, Robert K, et al.
Publicado: (2019)

P1591: HIGH RISK OF BLOOD STREAM INFECTION OF CRE CARRIERS IN NEUTROPENIC CHILDREN WITH HEMATOLOGICAL DISEASES
por: Liu, L.-P., et al.
Publicado: (2022)

1664. The Impact of Levofloxacin Prophylaxis on Empiric Intravenous Antibiotic Use in Pediatric Hematopoietic Stem Cell Transplant Recipients
por: Prodanuk, Michael, et al.
Publicado: (2023)

Levofloxacin prophylaxis vs no prophylaxis in patients with neutropenia within an endemic country for carbapenem-resistant GNB
por: Clerici, Daniela, et al.
Publicado: (2022)

1591 Hepatitis B outcome in coinfected HIV-HBV individuals in the tenofovir/emtricitabine era
por: Nguyen, Divien, et al.
Publicado: (2014)

2113. Infectious endocarditis in patients with hematologic malignancy at the University of Wisconsin
por: Scolarici, Michael J, et al.
Publicado: (2022)

1591. Antibiotic Utilization Trends in Veterans Affairs (VA) Patients with Carbapenem Resistant Enterobacteriaceae (CRE) Infections
por: Traversa, Alfredo, et al.
Publicado: (2020)

194. Antibiotic-resistant bloodstream infections in pediatric oncology patients on levofloxacin prophylaxis
por: Sridhar, Sunita, et al.
Publicado: (2020)

201. Safety and Effectiveness of Daily vs. Every Other Day Dosing of Daptomycin in Patients with Renal Insufficiency
por: Oliver, Meredith, et al.
Publicado: (2019)

Clinical Impact of Fluoroquinolone-Resistant Escherichia coli in the Fecal Flora of Hematological Patients with Neutropenia and Levofloxacin Prophylaxis
por: Chong, Yong, et al.
Publicado: (2014)

415. Breakthrough Invasive Fungal Infections in Adult Hematologic Malignancy Patients Receiving Isavuconazole Prophylaxis
por: DeVoe, Catherine, et al.
Publicado: (2018)

124. Impact of Levofloxacin MIC on Outcomes with Levofloxacin Step-down Therapy in Enterobacteriaceae Bloodstream Infections
por: White, Melissa, et al.
Publicado: (2019)

1542. Infectious Complications in Patients Following Umbilical Cord Blood Transplant (UCBT) for Hematologic Malignancy
por: Linder, Kathleen A, et al.
Publicado: (2018)

1139. Novel Formulation SUBA-Itraconazole Prophylaxis in Patients With Hematological Malignancy or Undergoing Allogeneic Stem Cell Transplantation: Follow-up Survival Data
por: Lindsay, Julian, et al.
Publicado: (2018)

755. Posaconazole versus voriconazole as antifungal prophylaxis for invasive fungal diseases in patients with hematological malignancies
por: Almutairy, Reem F, et al.
Publicado: (2020)

360. Breakthrough Invasive Pulmonary Aspergillosis During Isavuconazole Prophylaxis in Patients with Hematologic Malignancies: A Single-Center Experience
por: Fontana, Lauren, et al.
Publicado: (2018)

1591. Real-world experiences and outcomes implementing long-acting cabotegravir/rilpivirine at a Ryan White HIV/AIDS Program (RWHAP)-funded clinic in South Florida
por: Montalvo, Sheila, et al.
Publicado: (2023)

The tumor-rejection antigens of the 1591 ultraviolet fibrosarcoma. Potential origin and evolutionary implications
Publicado: (1989)

1908. Development of an Electronic Health Record Generated Alert for Prophylaxis Against Pneumocystis Jirovecii Pneumonia in the Setting of High-Dose Steroids
por: Goyal, Noopur, et al.
Publicado: (2018)

272. Invasive Pulmonary Aspergillosis: Comparative Analysis in cancer patients with Underlying Hematologic Malignancy vs. Solid Tumor
por: Wilson Dib, Rita, et al.
Publicado: (2019)

2709. Breakthrough fungal infection after isavuconazole primary prophylaxis in patients with hematologic malignancy and hematopoietic stem cell transplant: Systematic Review
por: Ishida, Keiko, et al.
Publicado: (2023)

Obesity and the Risk for a Hematological Malignancy: Leukemia, Lymphoma, or Myeloma
por: Lichtman, Marshall A.
Publicado: (2010)

Clinical Characteristics and Outcomes of Hematologic Malignancy Patients with Clostridium difficile Toxin EIA vs. PCR Positive Test Results
por: Ziegler, Matthew, et al.
Publicado: (2017)

Abstract No. : ABS1591: Effect of erector spinae block and PECS block on quality of recovery and analgesia after modified radical mastectomy
por: Mohsin, Md Hammad
Publicado: (2022)

1044 Efficacy of Ceftolozane/Tazobactam vs Levofloxacin in the Treatment of Complicated Urinary Tract Infections (cUTI) caused by Levofloxacin-resistant Pathogens: Results from the ASPECT-cUTI Trial
por: Sakoulas, George, et al.
Publicado: (2014)

1425. Population Pharmacokinetic Analysis of Ciprofloxacin and Levofloxacin in Critically Ill Trauma, Surgical, and Burn Patients
por: Ivins-O’Keefe, Kelly, et al.
Publicado: (2018)

Corrigendum to “Syk and ye shall find” [EBioMedicine 2 (11) (2015) 190-1591]
por: Wolozin, Benjamin, et al.
Publicado: (2016)

Single Dose of Levofloxacin versus Three Dosages for Prophylaxis in Prostate Biopsy
por: Linden-Castro, Edgar, et al.
Publicado: (2014)

1071. Impact of Standard vs. Prolonged Courses of Antibiotics for the Treatment of Uncomplicated Staphylococcus aureus Bacteremia (SAB) in Patients With Hematologic Malignancies
por: Cheung, Edna, et al.
Publicado: (2018)

2268. Clinical Implications of Azole-Resistant vs. Azole-Susceptible Invasive Aspergillosis in Hematological Malignancy (CLARITY): A Multicenter Study
por: Seidel, Danila, et al.
Publicado: (2019)

Impact of chlorhexidine mouthwash prophylaxis on probable ventilator-associated pneumonia in a surgical intensive care unit
por: Enwere, Emmanuel N, et al.
Publicado: (2016)

620. Sub-MIC Concentrations of Levofloxacin and Delafloxacin Enhance Staphylococcus aureus Biofilm Formation: Significance of Maximizing Exposure
por: Bodo, Emily C, et al.
Publicado: (2019)

1077. Infectious complications after second allogeneic hematopoietic cell transplant (allo-HCT) in adult patients with hematological malignancies
por: Maurer, Stephen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1rlacul3bn6sronptgr2vd78bg